CN Patent

CN108174596A — 包含8-[(3r)-3-氨基-1-哌啶基]-7-(2-丁炔-1-基)-3,7-二氢-3-甲基-1-[4-甲基-2-喹唑啉基)甲基]-1h-嘌呤-2,6-二酮或其药学上可接受的盐的药物组合物

Assigned to Hexal AG · Expires 2018-06-15 · 8y expired

What this patent protects

本发明涉及包括利拉利汀或其药学上可接受盐作为活性成分的药物组合物，其中所述药物组合物不包括粘合剂并且其中所述药物组合物通过直接压片获得。

USPTO Abstract

本发明涉及包括利拉利汀或其药学上可接受盐作为活性成分的药物组合物，其中所述药物组合物不包括粘合剂并且其中所述药物组合物通过直接压片获得。

Drugs covered by this patent

Patent Metadata

Patent number
CN108174596A
Jurisdiction
CN
Classification
—
Expires
2018-06-15
Drug substance claim
No
Drug product claim
No
Assignee
Hexal AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.